
Opinion|Videos|January 2, 2025
Understanding Ruxolitinib’s Mechanism of Action in Atopic Dermatitis
Author(s)Omar Noor, MD, FAAD
The panelist discusses how ruxolitinib treats atopic dermatitis by inhibiting Janus kinase (JAK)1/JAK2 signaling pathways to reduce inflammation and alleviate symptoms of the skin condition.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie to Acquire Apogee Therapeutics, Expanding AD Pipeline With Zumilokibart
2
Ycanth Phase 3 Trial Dosing Begins for Common Warts in US, Japan
3
The New Economics of Dermatology Claims: Understanding and Responding to Rising Denials
4
Striking the Balance with JAK Inhibitors in Atopic Dermatitis Management
5



















